Abstract:Monoclonal antibodies are of great use in research and clinic. The first monoclonal antibody production method, hybridoma technology, was marked in the paper "Continuous cultures of fused cells secreting antibody of predefined specificity" by Milstein and Kohler in 1975 in Nature. Based on that paper, we took a retrospective and forward look of this technique. In the early research of antibodies and B cells, the low specificity and bad reproductivity of polyclonal antibodies called for new methods to produce highly specific antibodies. Fortunately, the scientists encountered the key prerequisites of the hybridoma method: (1) Mouse multiple myeloma cell lines, which can secrete antibodies and infinitely reproduce in vitro; (2) SRBC (sheep red blood cell) plates that can screen the cells secreteing anti-SRBC antibodies; (3) proper cell fusion methods like Sendai virus and PEG. Based on all these materials and methods, Milstein and Kohler fused spleen cells of immunized mice with mouse myeloma cell line P3-X67Ag8 by inactivated Sendai virus and screened to clone the fused cells that can secrete anti-SRBC antibodies. They also used HAT medium to ensure that only fused cells from spleen cells and myeloma cells can survive. In this way, they obtained the immortal cells that can produce a single type of antibody with a predefined antigen-specificity, or say, hybridoma cells that can produce monoclonal antibodies. This powerful tool of hybridoma was quickly applied and improved. Milstein and Kohler were awarded the Nobel prize and Lasker award in 1984. Despite the great commercial potential of hybridoma in medication and science research, Milstein and Kohler did not patent the method, making it free to use by anyone in the world. The monoclonal antibodies produced by hybridoma were proved highly versatile in the laboratory. Besides great insights provided to us in basic immunology research, they become the indispensable tool to precisely qualify, quantify, and localize macromolecule in all fields of research. Fluorescence imaging, Western blotting, flow cytometry and microarray methods all make use of monoclonal antibodies. Upon chimera, humanized and human monoclonal antibody development, the application and success of monoclonal antibodies on the biopharma market are even greater. Monoclonal antibody medicines to treat cancer and autoimmune diseases are making billions of dollars every year. Notably, among these medicines, anti-PD-1 and anti-CTLA-4 are awarded Nobel prize in 2018 as anti-tumor immune checkpoint inhibitors. Monoclonal antibody medicines for contagious diseases like Ebola also shows advantages over others. For the new outbreak of COVID-19 around the world, monoclonal antibodies are also promising in offering new cures. Presently, the production of monoclonal antibodies is no longer solely dependent on hybridoma technology. Transgenic and recombinant DNA technology are creating new possibilities in this ever-growing field.

Technology Changes Drive Legal Changes for Antibody Patents: What Patent Examiners Can Teach Courts About the Written Description and Enablement Requirements

Biotechnology Patent Law Top Ten of 2022: Inducement, Clear Error, and Interferences Galore

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Antibody Conjugates-Recent Advances and Future Innovations

The history of monoclonal antibody development – Progress, remaining challenges and future innovations

The Evolution of Commercial Antibody Formulations

New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

The role of therapeutic antibodies in drug discovery

The Current Landscape of Antibody-based Therapies in Solid Malignancies

Improvement of Therapeutic Antibodies

Monoclonal Antibodies: Emergence, Present and Outlook

Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

Advances in Antibody Drug Expression Techniques

A Singular Disclosure Requirement Is Necessary For Patent Law

Monoclonal antibodies: technologies for early discovery and engineering

Development of therapeutic antibodies for the treatment of diseases

Leveraging Artificial Intelligence to Expedite Antibody Design and Enhance Antibody–Antigen Interactions

How Biologics Have Changed the Drug Discovery Landscape

Analysis of aptamer discovery and technology

Biophysical properties of the clinical-stage antibody landscape